Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13

Impact · against what's priced in

Artelo Biosciences gains significant valuation support from positive interim Phase 2 data for ART27.13 in cancer-related anorexia and the securing of key IP protection in Japan. The combined clinical efficacy and global patent estate increase the asset's attractiveness for future partnerships or acquisition.

ARTL+0.70

No priced-in read yet